Eli Lilly has strategically terminated two of the three ongoing phase 2 trials of its oral GLP-1 candidate naperiglipron citing 'strategic business reasons,' while continuing a pivotal trial slated for completion in 2026. Concurrently, Lilly's lead oral GLP-1 drug, orforglipron, demonstrated a 10.5% mean weight reduction in a Phase 3 trial in obese or overweight adults, reinforcing its clinical relevance. Despite this, investor response has been mixed, reflecting the competitive and high-expectation landscape in GLP-1 obesity therapeutics. Additionally, Teva received FDA approval for the first generic injectable GLP-1 agonist liraglutide for weight loss, potentially impacting market dynamics by addressing supply shortages and costs.